Is phage therapy acceptable in the immunocompromised host?
Is phage therapy acceptable in the immunocompromised host?
复制标题
DOI：
10.1016/j.ijid.2008.01.006
复制
发表时间：
2008-09-01
影响因子：
8.4
通讯作者：
Gorski, Andrzej
中科院分区：
文献类型：
--
作者：
Borysowski, Jan;Gorski, Andrzej
在过去的十年中，噬菌体（细菌病毒）已成为抗生素治疗耐药性感染的主要替代品。白色已经积累了相当多的证据证明噬菌体疗法在免疫功能正常的患者中的有效性和安全性，但关于其在免疫功能低下的宿主中的使用的数据仍然相对缺乏。据我们所知，本文章是第一个总结所有的研究结果，实验和临床研究，这可能是相关的就业噬菌体治疗免疫功能低下的患者。现有数据表明，噬菌体也可能是此类患者的有效和安全的治疗方式。(C)2008年国际传染病学会。由爱思唯尔有限公司出版。保留所有权利。
Over the last decade, bacteriophages (bacterial viruses) have emerged as the major alternative to antibiotics in the treatment of antibiotic-resistant infections. White a considerable body of evidence has accumulated for the efficacy and safety of phage therapy in immunocompetent patients, data remain relatively scarce regarding its use in the immunocompromised host. To our knowledge, the present article is the first to summarize all findings, of both experimental and clinical studies, that may be relevant to the employment of phage therapy in immunocompromised patients. The available data suggest that bacteriophages could also be an efficacious and safe therapeutic modality in such patients. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.